NCT05702229 2026-03-18
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
Clinical Trials
14 trialsNCT06253611 2025-09-22
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT03662659 2025-02-05
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
Phase 2 Completed
NCT06123455 2023-11-08
Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer
Tang-Du Hospital
Phase 2 Unknown
NCT03939962 2022-01-26
Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma
Henan Cancer Hospital
Phase 2 Unknown
NCT02845908 2021-04-23
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
Fujian Cancer Hospital
Phase 2 Completed
NCT03528876 2020-11-02
LOGIC
University of Saskatchewan
Phase 2 Terminated
NCT01498289 2019-11-07
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT04155671 2019-11-07
POF Versus FOLFOX Plus IP Paclitaxel in AGC
Fujian Cancer Hospital
Phase 2 Unknown
NCT02486601 2019-02-27
FOXAGAST
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Unknown
NCT01283204 2019-01-29
Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer
Yonsei University
Phase 2 Completed
NCT02215837 2016-05-24
Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT00673673 2015-02-04
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Yale University
Phase 2 Completed
NCT00004127 2013-02-11
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach
University of Chicago
Phase 2 Completed